Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone617-876-8191
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$230,000.00
Profitability
Miscellaneous
Employees61
Next Earnings Date10/24/2019 (Confirmed)
OptionableOptionable
Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions
What is Genocea Biosciences' stock symbol?
Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."
How were Genocea Biosciences' earnings last quarter?
Genocea Biosciences Inc (NASDAQ:GNCA) released its earnings results on Thursday, July, 25th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.65) by $0.02. View Genocea Biosciences' Earnings History.
When is Genocea Biosciences' next earnings date?
How can I listen to Genocea Biosciences' earnings call?
Genocea Biosciences will be holding an earnings conference call on Thursday, October 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for GNCA?
3 brokers have issued 12 month target prices for Genocea Biosciences' stock. Their predictions range from $16.00 to $32.00. On average, they anticipate Genocea Biosciences' stock price to reach $24.00 in the next year. This suggests a possible upside of 819.5% from the stock's current price. View Analyst Price Targets for Genocea Biosciences.
What is the consensus analysts' recommendation for Genocea Biosciences?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genocea Biosciences.
What are Wall Street analysts saying about Genocea Biosciences stock?
Here are some recent quotes from research analysts about Genocea Biosciences stock:
- 1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (9/25/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and are lowering our price target to $32 from $42 to reflect the recent dilution, and fully diluted share count from the company’s equity raise." (7/25/2019)
Has Genocea Biosciences been receiving favorable news coverage?
Media headlines about GNCA stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Genocea Biosciences earned a coverage optimism score of -2.5 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Genocea Biosciences.
Are investors shorting Genocea Biosciences?
Genocea Biosciences saw a decrease in short interest in September. As of September 30th, there was short interest totalling 178,400 shares, a decrease of 8.3% from the August 30th total of 194,500 shares. Based on an average trading volume of 148,300 shares, the short-interest ratio is presently 1.2 days. Approximately 1.2% of the company's shares are sold short. View Genocea Biosciences' Current Options Chain.
Who are some of Genocea Biosciences' key competitors?
Some companies that are related to Genocea Biosciences include BioCryst Pharmaceuticals (BCRX), Eiger Biopharmaceuticals (EIGR), Sutro Biopharma (STRO), La Jolla Pharmaceutical (LJPC), LogicBio Therapeutics (LOGC), Compugen (CGEN), Dyadic International (DYAI), X4 Pharmaceuticals (XFOR), Oncobiologics (ONS), Allena Pharmaceuticals (ALNA), Axcella Health (AXLA), Gamida Cell (GMDA), Jounce Therapeutics (JNCE), Acorda Therapeutics (ACOR) and Nantkwest (NK).
What other stocks do shareholders of Genocea Biosciences own?
Who are Genocea Biosciences' key executives?
Genocea Biosciences' management team includes the folowing people:
- Mr. William D. Clark M.B.A., Pres, CEO & Director (Age 50)
- Dr. Jessica Baker Flechtner, Chief Scientific Officer (Age 47)
- Dr. George R. Siber M.D., Ph.D., Chairman of Scientific Advisory Board & Exec. Director (Age 74)
- Mr. Michael Alfieri, VP of Fin., Principal Financial Officer & Principal Accounting Officer (Age 54)
- Ms. Pamela Carroll, Sr. VP of Immun-Oncology (Age 55)
How do I buy shares of Genocea Biosciences?
Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Genocea Biosciences' stock price today?
One share of GNCA stock can currently be purchased for approximately $2.61.
How big of a company is Genocea Biosciences?
Genocea Biosciences has a market capitalization of $68.25 million and generates $230,000.00 in revenue each year. The biotechnology company earns $-27,810,000.00 in net income (profit) each year or ($3.68) on an earnings per share basis. Genocea Biosciences employs 61 workers across the globe.View Additional Information About Genocea Biosciences.
What is Genocea Biosciences' official website?
How can I contact Genocea Biosciences?
Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected]
MarketBeat Community Rating for Genocea Biosciences (NASDAQ GNCA)
MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote "Outperform" if you believe GNCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
